M
41.75
-0.25 (-0.60%)
| Penutupan Terdahulu | 42.00 |
| Buka | 42.20 |
| Jumlah Dagangan | 3,279,647 |
| Purata Dagangan (3B) | 7,642,422 |
| Modal Pasaran | 16,066,150,400 |
| Harga / Jualan (P/S) | 3.20 |
| Harga / Buku (P/B) | 1.36 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Feb 2025 - 24 Feb 2025 |
| Margin Keuntungan | -43.77% |
| Margin Operasi (TTM) | -3.76% |
| EPS Cair (TTM) | -5.81 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.36% |
| Nisbah Semasa (MRQ) | 4.39 |
| Aliran Tunai Operasi (OCF TTM) | -3.21 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.34 B |
| Pulangan Atas Aset (ROA TTM) | -9.55% |
| Pulangan Atas Ekuiti (ROE TTM) | -17.52% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Moderna, Inc. | Menaik | Menurun |
AISkor Stockmoo
0.8
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.80 |
|
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 9.52% |
| % Dimiliki oleh Institusi | 71.64% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Theleme Partners Llp | 30 Sep 2024 | 7,226,861 |
| Flagship Pioneering Inc. | 30 Sep 2024 | 4,632,149 |
| Banque Pictet & Cie Sa | 30 Sep 2024 | 3,155,399 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 111.00 (Barclays, 165.87%) | Beli |
| Median | 55.00 (31.74%) | |
| Rendah | 38.00 (Morgan Stanley, -8.98%) | Pegang |
| Purata | 61.44 (47.16%) | |
| Jumlah | 4 Beli, 2 Pegang, 3 Jual | |
| Harga Purata @ Panggilan | 42.08 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 15 Jan 2025 | 38.00 (-8.98%) | Pegang | 34.46 |
| UBS | 08 Jan 2025 | 96.00 (129.94%) | Beli | 43.17 |
| 24 Oct 2024 | 108.00 (158.68%) | Beli | 52.80 | |
| B of A Securities | 10 Dec 2024 | 41.00 (-1.80%) | Jual | 41.51 |
| JP Morgan | 26 Nov 2024 | 45.00 (7.78%) | Jual | 42.05 |
| 04 Nov 2024 | 59.00 (41.32%) | Jual | 53.54 | |
| HSBC | 18 Nov 2024 | 58.00 (38.92%) | Beli | 39.51 |
| Piper Sandler | 18 Nov 2024 | 69.00 (65.27%) | Beli | 39.51 |
| Wolfe Research | 15 Nov 2024 | 40.00 (-4.19%) | Jual | 36.85 |
| Barclays | 08 Nov 2024 | 111.00 (165.87%) | Beli | 46.83 |
| Bernstein | 17 Oct 2024 | 55.00 (31.74%) | Pegang | 54.82 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MOCK JAMES M | - | 42.18 | -780 | -32,900 |
| Jumlah Keseluruhan Kuantiti Bersih | -780 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -32,900 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 42.18 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MOCK JAMES M | Pegawai | 03 Jan 2025 | Dibuang (-) | 780 | 42.18 | 32,900 |
| MOCK JAMES M | Pegawai | 03 Jan 2025 | Pelaksanaan pilihan | 1,453 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |